The orosomucoid-like proteins (Ormdl1-3) are emerging as the critical regulators of sphingolipid homeostasis, inflammation and ER stress. However, their roles in β-cells and obesity remain unknown. Here, we showed that islets isolated from overweight/obese human donors displayed marginally reduced ORMDL1-2 expression while ORMDL3 expression was significantly reduced as compared to islets from lean donors. In contrast, Ormdl3 expression was significantly upregulated in the islets of leptin-deficient obese (ob/ob) mice compared to lean mice. We identified that the difference in expression of Ormdl3 between mouse and human islets was leptin-dependent, as treatment of ob/ob mice with leptin significantly reduced Ormld3 expression. Furthermore, Ormdl1-3 were significantly upregulated upon chemically-induced ER stress, but they showed differential responsiveness to cytokines in a b-cell line. Knockdown of Ormdl3 substantially increased expression of apoptotic markers, which was rescued by a pharmacological inhibitor of ceramide synthase. Taken together we demonstrate leptin-dependent regulation of Ormdl3 expression in ob/ob islets, highlight the possible importance of b-cell stress conditions in differential Ormdl expression and identify a critical role for Ormdl3 in b-cell survival.
Introduction
Insulin resistance, often co-incident with obesity, dampens the brake on lipolysis, elevating plasma free fatty acid levels. Free fatty acids taken up from the plasma are the precursors for various species of intracellular lipids. Certain sphingolipids, most notably, ceramide, accumulate within insulin-resistant tissues of animals 1, 2 and humans 3, 4 , including the pancreatic β-cell. 5 There, they inhibit insulin action, activating processes including apoptosis, inflammation, and stress responses-a condition known as lipotoxicity. De novo sphingolipid synthesis, where fatty acids from exogenous sources are utilized as substrates, is primarily responsible for obesity-induced ceramide generation 6, 7 . Serine palmitoyltransferase (SPT), which catalyzes the decarboxylative condensation of L-serine and palmitoyl-CoA to 3-ketodihydrosphingosine, initiates de novo sphingolipid synthesis.
Surplus exogenous fatty acids not only lead to increased substrate availability, but also alter expression and activity of key enzymes in the sphingolipid synthetic pathway. SPT functions as a heterodimer of subunits SPTLC1 or SPTLC2 with SPTLC3, and high fat diet feeding promotes both SPT subunit gene transcription and catalytic activity 8,9 10 . Yet, despite recent progress in the field, the molecular mechanisms of sphingolipid-mediated disease pathology and the pathways generating these pathogenic lipids remain poorly understood.
The members of the orosomucoids (Orm) gene family encode transmembrane proteins localized in the endoplasmic reticulum (ER). While the budding yeast S. cerevisiae has two Orm genes (Orm1 and Orm2) 11 , mammalians have three Orm-like proteins (Ormdl1-3) 12 .
While Orm protein sequences are highly conserved among species, little information has been identified regarding the mechanisms of action or regulation of activity of Orm family proteins. Orm1 and Orm2 were recently identified as negative regulators of SPT. Orm proteins form a complex with SPT and inhibit its activity. This association with SPT is regulated by Orm protein phosphorylation: an important factor for sphingolipid homeostasis 13 .
In vitro studies have suggested that mammalian Ormdl3 alters ER-mediated calcium (Ca 2+ ) homeostasis, facilitates the unfolded protein response (UPR), induces cellular stress responses, and may play a role in inflammation [14] [15] [16] [17] . In human genome wide association studies, ORMDL3 is strongly associated with inflammatory diseases, including asthma, Crohn's disease, and type 1 diabetes (T1D) [18] [19] [20] [21] [22] [23] [24] . Although emerging data suggest Ormdl proteins are involved in sphingolipid homeostasis, chronic inflammation, and ER stress-all of which play critical roles in the development and progression of obesity, diabetes, and β-cell dysfunction-the expression, function, and importance of Ormdl genes in β-cell physiology and pathology currently remains unknown. Here, we analyzed the expression of Ormdl genes in a βcell line under various cellular stress conditions, in a genetic mouse model of obesity and type 2 diabetes prior to the onset of hyperglycemia, and in human pancreatic islets isolated from lean and obese non-diabetic donors. Our results for the first time, revealed obesity-, species-and sexdependent differences in Ormdl family member expression in pancreatic islets. We also identified that expression of Ormdl1-3 were significantly increased upon chemically-induced ER stress, but they showed differential responsiveness to cytokine-induced stress in a mouse b-cell line. Moreover, our data highlight that leptin can regulate Ormdl3 expression and provide an explanation for differential expression of this gene in mouse and human islets in the context of obesity. Finally, we demonstrated that among the Ormdl genes knockdown of Ormdl3 cause substantially increased b-cell death and upregulation of apoptotic markers.
The cell death phenotype was markedly rescued by treatment of cells with a chemical inhibitor of ceramide synthase suggesting Ormdl3-sphingolipid-ceramide axis can play an important role in b-cell survival.
Results

Overweight/obese human islets display significantly reduced expression of ORMDL3
To identify the pancreatic islet ORMDL expression in the context of obesity, we used pancreatic islets isolated from lean and obese human organ donors. We grouped donors as lean (BMI≤25) and overweight/obese (BMI>25) ( Table 1 ). All ORMDL genes showed a trend toward diminished mRNA expression in islets isolated from obese humans as compared to lean (as quantified by cycle threshold as compared to b-actin), with the cycles necessary to amplify ORMDL3 PCR product being significantly reduced (approximately 3.5 cycles, or 11fold) (Figures 1a-c). We next examined the relationship between islet ORMDL expression and donor sex. Interestingly, the cycle threshold necessary to amplify ORMDL2 and ORMDL3 expression was significantly reduced (by approximately 5-5.5 cycles) in islets from overweight/obese female donors only, corresponding with a 32-45-fold decrease in mRNA expression with obesity ( Figures 1d-f ). ORMDL1 expression level was non-significantly decreased in islets from female donors as a factor of overweight/obesity. Although no significant changes in the expression of any ORMDL family member were observed in islets isolated from male donors as a factor of overweight/obesity, the mean ORMDL3 cycle threshold in islets from overweight/obese male donors was reduced as compared to lean (Figures 1d-f).
To rule out a potential confounder in our human islet analyses, we examined the correlation between ORMDL expression and donor age and did not detect any significant correlation (Figures S1a-c).
Ormdl3 expression is significantly upregulated in leptin-deficient obese (ob/ob) mice.
In rodent models of obesity, increased islet ceramide and triglyceride production precede β-cell dysfunction and destruction. Therefore, we examined whether the expression of Ormdl genes was altered in the pancreatic islets of genetically-induced leptin-deficient obese (ob/ob) mice, a model of severe insulin resistance and lipotoxicity. First, we analyzed the expression of Ormdl genes in lean or obese (ob/ob) male mice on C57BL/6J background at 10 weeks of age, while obese mice were still normoglycemic. Quantitative PCR analysis indicated that while expression of Ormdl1 and Ormdl2 non-significantly enhanced, Ormdl3 expression was substantially upregulated in islets from male ob/ob mice as compared to lean mice (Figures 2a-c). To explore any sex-specific differences in islet Ormdl expression with obesity, we assessed the expression of the Ormdl genes in islets harvested from 10-week-old female C57BL/6J mice, both lean and obese. The cycles necessary to amplify Ormdl1 and Ormdl2 PCR product were nearly identical between islets isolated from lean and obese female C57BL/6J mice, whereas female ob/ob islets, similar to islets of male mice, showed significantly increased expression of Ormdl3 (Figures 2d-f ).
Next, we investigated the expression of Ormdls at the protein level. Ormdl1, -2 and -3 share greater than 80% sequence homology. Currently, there are no commercially available antibodies that can detect specific expression of the individual Ormdl family members. In addition, three commercially available pan-Ormdl antibodies failed validation using knockdown lysates (data not shown). We obtained a TPF-Ormdl antibody from Dr. Petr Draber's group 25 and although the antibody had significant non-specific cross-reactivity, transfection with an Ormdl3 siRNA resulted in a specific decrease in the abundance of a protein at the expected molecular weight for Ormdl (17.5 kD) that was well-removed from any other non-specific band, confirming the validity of this antibody for further analyses (Figures S2a-c). Using this antibody, we demonstrated Ormdl protein levels were also significantly upregulated in islets of male ob/ob mice, consistent with changes in mRNA expression ( Figure 2g ).
Leptin administration markedly reduces Ormdl3 expression in ob/ob islets
Our data reveal that the expression of Ormdl3 in mouse and human islets were altered in the opposite direction. One explanation for these disparate results could have been the effect of the adipokine leptin. Obesity in humans is known to be associated with increased circulating leptin, while ob/ob mice are leptin deficient. To test this, we treated 10-week-old male normoglycemic ob/ob mice with recombinant leptin for four days. Interestingly, while we did not detect a significant effect of leptin treatment on the expression of Ormdl1 and 2, Ormld3 expression was significantly reduced in ob/ob islets upon leptin treatment, similar to that observed in human islets from obese donors as compared to lean (Figures 3a-c). Mean blood glucose levels in ob/ob mice were not significantly changed by leptin treatment, but an approximate 10% reduction in bodyweight was observed, as previously reported 26, 27 (Figures   3d and 3e ). These results indicate that the leptin can play a key role in Ormdl3 transcriptional regulation and provide an explanation for the differential expression pattern that we observed in islets obtained from overweight/obese human donors and leptin deficient ob/ob mice.
Chemically-induced ER stress upregulates the expression of Ormdl1-3
Accumulation of the sphingolipid, ceramide, can lead to ER stress. Localized ceramide production and an associated decrease in ER sphingomyelin levels in response to lipotoxicity is an important initiator of ER stress in the β-cell. To evaluate whether ER stress itself can alter β-cell expression of Ormdl genes, we first treated a mouse insulinoma cell line, MIN6, with a chemical ER stress inducer, tunicamycin, for 24 hours. Tunicamycin-treated MIN6 cells had higher expression of all three Ormdl family members than control-treated cells, with expression of Ormdl1, 2 and Ormdl3 being significantly increased (by approximately 3-fold) (Figures 4a-c). In contrast, treating MIN6 cells with a pro-inflammatory cytokine cocktail had little-to-no impact on Ormdl mRNA expression, save a small (1.2-fold) but statistically significant increase in Ormdl1 mRNA (Figures 4a-c). Next, we examined the effects of thapsigargin, cytokines, and an additional ER stressor, tunicamycin, on total Ormdl protein expression at 8-and 24 hours post-treatment in MIN6 cells. We confirmed thapsigargin and tunicamycin upregulated the ER stress pathway by Western blot for spliced Xbp1 (sXbp1) and the chaperone, GRP78. sXbp1 was increased at 8 hours and GRP78 at 24 hours with thapsigargin and tunicamycin treatment, as expected (Figures 4d and 4e ). Total Ormdl expression was significantly increased 8 hours after initiation of treatment with ER stressors ( Figure 4d) , and, at 24 hours, Ormdl protein expression was markedly increased upon induction of ER stress ( Figure 4e ). Despite these changes in expression levels with chemical ER stress inducers, we have not detected any significant alterations in the protein levels of Ormdl genes at the indicated time points upon cytokine cocktail treatment. Ormdl3 has been reported to regulate ER stress and the UPR. Thus, we investigated whether β-cell death observed in Ormdl3 deficient cells was due to increased ER stress and/or dysfunctional UPR. We did not observe any significant changes in the mRNA or protein levels of the UPR markers sXbp1, Grp78, Chop or Atf6 in INS-1 832/3 cells transfected with siOrmdl3 alone or in the presence of ER stressor thapsigargin (Figures 6a-e ). These data suggest that Ormdl3 deficiency does not trigger ER stress or ER stress-mediated cell death in INS-1 832/3 cells. Next, we hypothesized that Ormdl3 deficiency might increase ceramide production and subsequently lead to β-cell death as Orm proteins known to suppress sphingolipid biosynthesis and ceramides, which are known to be important mediators β-cell dysfunction and apoptosis 21, 22 . If this is the case, blocking the ceramide synthesis downstream of sphingolipid synthesis by using a pharmacological inhibitor of ceramide synthase, Fumonisin B1, should have reduced the cell death. To test this hypothesis, we treated Ormdl3 deficient INS-1 cells with Fumonisin B1, an inhibitor of de novo ceramide biosynthesis, and assessed protein levels of apoptosis markers via western blotting. Consistent with our hypothesis, levels apoptotic markers, caspase-3 and cleaved-Parp, were markedly reduced upon inhibition of ceramide synthase in INS-1 832/3 cells ( Figure 6f ).
Knockdown of Ormdl3 leads to β-cell death
Discussion
A growing body of evidence has suggested the genetic association of ORMDL3 gene polymorphisms with a diverse set of inflammatory disorders that include bronchial asthma, inflammatory bowel disease, ankylosing spondylitis, T1D, and atherosclerosis. We have recently shown aberrant β-cell ER stress is linked to T1D pathogenesis, and that there is abnormal β-cell UPR activity in both type 1 and type 2 diabetes animal models and human patients suggesting that highly conserved cellular mechanisms can play a critical role in the pathology of both types of diabetes [28] [29] [30] . Hence, due to their involvement with inflammatory diseases, regulation of sphingolipid biosynthesis, and ER stress we hypothesized that Ormdls could play an important role in β-cell homeostasis, and we investigated the regulation of these genes in pancreatic islets in the context of obesity. One of the most intriguing findings of our study was islet ORMDL3 expression was significantly influenced by obesity in both mouse and human samples, albeit in opposing directions. ORMDL3 mRNA expression was significantly reduced in islets isolated from overweight/obese human female organ donors while Ormdl3 expression was actually increased in islets from both female and male ob/ob mice, the latter significantly. We reasoned that these contrasting results might be due to leptin as while obese humans have significantly increased levels of circulating leptin, ob/ob mice are deficient of this adipokine. Indeed, administration of leptin to male ob/ob mice only for four days significantly reduced Ormdl3 expression in islets, indicating that leptin may have a regulatory role in Ormdl3 expression. Interestingly, central leptin signaling represses SPT expression in white adipose tissue by 30% 31 and decreases mRNA expression of enzymes involved in de novo ceramide synthesis (SPT-1, LASS2, LASS4) and ceramide production from sphingomyelin (SMPD-1/2) 31 . Leptin receptor overexpression in the islets of obese Zucker diabetic fatty (ZDF) rats with mutant leptin receptors leads to significantly reduced SPT mRNA and fat content 32, 33 . However, whether such a regulation also exists in human islets is not yet known. Since ob/ob mice have elevated circulating free fatty acids and increased ceramide in their islets 34 , it is possible that upregulated Ormdl3 levels in ob/ob mice in the absence of leptin exert compensatory inhibitory effects on sphingolipid synthesis, whereas in obese, hyperleptinemic human subjects, downregulation of ORMDL3 may lead to increased ceramide synthesis and lipotoxicity in islets. Of note, while leptin resistance in the hypothalamus is well established in obesity and diabetes, such resistance has not been definitively demonstrated in pancreatic β-cells. Leptin levels are also higher in women than in men using any given measure of obesity; a finding that may provide insight into the sex-dependent differential expression of ORMLD2 and ORMDL3.
Recent studies suggested the genetic association of ORMDL3 polymorphisms with a diverse set of inflammatory disorders that include bronchial asthma, inflammatory bowel disease, ankylosing spondylitis, T1D, and atherosclerosis. Hence, we tested whether cytokines and ER stress, which play a key role in the pathogenesis of many inflammatory diseases would affect Ormdl expression. Interestingly, while we did not detect a major change in the expression of Ormdl genes in MIN6 cells in response to cytokines, however chemically-induced ER stress significantly upregulated Ormdl3 in these cells. Since cytokines known to induce ER stress, whether under prolonged cytokine exposure and various dose regimes inflammatory cytokines alter Ormdl gene expression in an ER stressdependent matter will need further investigation. Emerging data indicate that Ormdl3 promotes ER stress and the UPR 15, 16 , here we show that Ormdl3 itself can be regulated by chemically-induced ER stress, but not induce ER stress in a β-cell line. In addition, we demonstrated that even in the absence of any additional stressor, deficiency of Ormdl3 leads to β-cell death and upregulation of apoptotic markers in INS-1 832/3 cells which can be significantly reduced by administration of a pharmacological inhibitor of ceramide synthesis. This demonstrates for the first time that Ormdl3 plays an important role in β-cell survival.
However, the exact function and regulation of Ormdl3 in β-cells will need to be identified using tissue-specific genetic loss and gain of function models.
Our findings do not clarify whether Ormdl protein function itself was altered under the conditions of obesity and/or inflammation. In yeast, Orm proteins are regulated through phosphorylation 35, 36 . Although, Orm proteins are highly conserved in higher organisms, Ormdl proteins have a truncated N-terminal domain and lack the phosphorylation motif found in yeast, indicating divergent post-translational regulatory mechanisms 37 . Emerging data indicate that Ormdl genes might be transcriptionally regulated: when sphingolipid degradation was compromised by deletion of the lyase enzyme, low SPT activity paralleled a considerable elevation in Ormdl1 and Ormdl3 transcription 38 . In addition, ORMDL expression strongly influenced SPT activity and de novo ceramide synthesis in macrophages 39 . The molecular mechanisms of regulation of Ormdl transcription and post-translational processing still needs detailed investigation.
To summarize, our data provide the first comprehensive analysis of ORMDL family gene expression in mouse and human islets in the context of obesity. Furthermore, we demonstrate that Ormdl gene expression is responsive to ER stress, a cellular stress condition that is associated with obesity, in a mouse b-cell line. We also demonstrate that 
Limitations of the study
While our study reveals for the first time the expression of the Ormdl genes in the islets of both obese mice and humans, it does not address the protein levels in human samples mainly due to the limited sources of human samples and the specific antibody. Further mechanistic studies by using primary islets and in vivo loss and gain of function models will be necessary to definitively demonstrate the function and regulation of these genes in β-cell pathophysiology. 
Methods
RNA extraction and qPCR analysis
Total RNA was extracted using TRIzol reagent (Invitrogen) from MIN6 cells. cDNAs were synthesized from extracted RNA by using Superscript III First Strand RT-PCR kit (Invitrogen). All human islet cycle thresholds were normalized to b-actin.
Donor human islets
Human islets were obtained from the Integrated Islet Distribution Program (IIDP) according to an approved IRB exemption protocol stating this work is not human subjects research (UW 2012-0865). Islets were cultured in RPMI 1640 with 8 mM glucose for 24 hours before being pelleted for RNA.
Primary mouse islet Isolation
Islets were isolated by using the standard collagenase/protease digestion method. Briefly, the pancreatic duct was cannulated and distended with collagenase solution using Collagenase type XI (Sigma-Aldrich). Islets were separated from the exocrine tissue using Histopaque (Sigma-Aldrich) gradient. Hand-picked islets were counted prior to the experiments.
Western Blot
Cells or islets were lysed in RIPA buffer (50 mM Tris, pH 7.4, 150 mM, NaCl, 5 mM EDTA, pH d. e. f. 
